Profile - To The Moon

COGAN

Posts · 3Posts · 3
Following · 0Following · 0
Followers · 0Followers · 0

- COGANCOGAN
  ·2021-06-22
  whoo hooo!!!
  EMA Says CHMP Approves 2 Additional Manufacturing Sites For Biontech/Pfizer's COVID-19 Vaccine
  European Medicines Agency:Ema : Two Additional Manufacturing Sites For Biontech/Pfizer’S Covid-19 Va
  EMA Says CHMP Approves 2 Additional Manufacturing Sites For Biontech/Pfizer's COVID-19 Vaccine
  153 Comment
  Like
  Share
  Report
- COGANCOGAN
  ·2021-06-15
  $Microsoft(MSFT)$beginner's luck :)
  557 2
  Like
  Share
  Report
- COGANCOGAN
  ·2021-06-02
  cool
  Singapore Allows Sinovac Vaccine After WHO Emergency Approval
  Singapore will allow the use of Sinovac Biotech Ltd.’s Covid-19 vaccine, after the World Health Orga
  Singapore Allows Sinovac Vaccine After WHO Emergency Approval
  281 Comment
  Like
  Share
  Report

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3583781718374593","uuid":"3583781718374593","gmtCreate":1620687730392,"gmtModify":1620687730392,"name":"COGAN","pinyin":"cogan","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":2,"tweetSize":3,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.02.05","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.06.07","exceedPercentage":"60.47%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":129658702,"gmtCreate":1624371963606,"gmtModify":1703834776249,"author":{"id":"3583781718374593","authorId":"3583781718374593","name":"COGAN","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583781718374593","authorIdStr":"3583781718374593"},"themes":[],"htmlText":"whoo hooo!!!","listText":"whoo hooo!!!","text":"whoo hooo!!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/129658702","repostId":"2145052264","repostType":2,"repost":{"id":"2145052264","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"T-Reuters","id":"1086160438","head_image":"https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5"},"pubTimestamp":1624364681,"share":"https://ttm.financial/m/news/2145052264?lang=&edition=fundamental","pubTime":"2021-06-22 20:24","market":"us","language":"en","title":"EMA Says CHMP Approves 2 Additional Manufacturing Sites For Biontech/Pfizer's COVID-19 Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2145052264","media":"T-Reuters","summary":"European Medicines Agency:Ema : Two Additional Manufacturing Sites For Biontech/Pfizer’S Covid-19 Va","content":"<html><body><p>European Medicines Agency:Ema : <a href=\"https://laohu8.com/S/TWOA.U\">Two</a> Additional Manufacturing Sites For Biontech/Pfizer’S Covid-19 Vaccine :22/06/2021.Ema - One Site, Located In Reinbek, Germany, Operated By Allergopharma Gmbh &amp; Co. Kg. The Other In Stein, Switzerland, Is Operated By Novartis Pharma.Ema Says  One Site, Located In Reinbek, Germany, Is Operated By Allergopharma Gmbh &amp; Co. Kg..Ema Says The <a href=\"https://laohu8.com/S/TWOA\">Two</a> New Sites Are Expected To Support The Continued Supply Of Comirnaty In The European Union..Ema Says This Recommendation Does Not Require A European Commission Decision And The Sites Can Become Operational Immediately.Further Company Coverage: Pfe.N. ((Reuters.Briefs@Thomsonreuters.Com ;;)).</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EMA Says CHMP Approves 2 Additional Manufacturing Sites For Biontech/Pfizer's COVID-19 Vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEMA Says CHMP Approves 2 Additional Manufacturing Sites For Biontech/Pfizer's COVID-19 Vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086160438\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a113a995fbbc262262d15a5ce37e7bc5);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">T-Reuters </p>\n<p class=\"h-time\">2021-06-22 20:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>European Medicines Agency:Ema : <a href=\"https://laohu8.com/S/TWOA.U\">Two</a> Additional Manufacturing Sites For Biontech/Pfizer’S Covid-19 Vaccine :22/06/2021.Ema - One Site, Located In Reinbek, Germany, Operated By Allergopharma Gmbh &amp; Co. Kg. The Other In Stein, Switzerland, Is Operated By Novartis Pharma.Ema Says  One Site, Located In Reinbek, Germany, Is Operated By Allergopharma Gmbh &amp; Co. Kg..Ema Says The <a href=\"https://laohu8.com/S/TWOA\">Two</a> New Sites Are Expected To Support The Continued Supply Of Comirnaty In The European Union..Ema Says This Recommendation Does Not Require A European Commission Decision And The Sites Can Become Operational Immediately.Further Company Coverage: Pfe.N. ((Reuters.Briefs@Thomsonreuters.Com ;;)).</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.trkd.thomsonreuters.com","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145052264","content_text":"European Medicines Agency:Ema : Two Additional Manufacturing Sites For Biontech/Pfizer’S Covid-19 Vaccine :22/06/2021.Ema - One Site, Located In Reinbek, Germany, Operated By Allergopharma Gmbh & Co. Kg. The Other In Stein, Switzerland, Is Operated By Novartis Pharma.Ema Says  One Site, Located In Reinbek, Germany, Is Operated By Allergopharma Gmbh & Co. Kg..Ema Says The Two New Sites Are Expected To Support The Continued Supply Of Comirnaty In The European Union..Ema Says This Recommendation Does Not Require A European Commission Decision And The Sites Can Become Operational Immediately.Further Company Coverage: Pfe.N. ((Reuters.Briefs@Thomsonreuters.Com ;;)).","news_type":1},"isVote":1,"tweetType":1,"viewCount":153,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187830399,"gmtCreate":1623748659611,"gmtModify":1704210333824,"author":{"id":"3583781718374593","authorId":"3583781718374593","name":"COGAN","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583781718374593","authorIdStr":"3583781718374593"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MSFT\">$Microsoft(MSFT)$</a>beginner's luck :)","listText":"<a href=\"https://laohu8.com/S/MSFT\">$Microsoft(MSFT)$</a>beginner's luck :)","text":"$Microsoft(MSFT)$beginner's luck :)","images":[{"img":"https://static.tigerbbs.com/1742dc0f255ddb39d7ee5d117af555d6","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/187830399","isVote":1,"tweetType":1,"viewCount":557,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":111099656,"gmtCreate":1622643006575,"gmtModify":1704187944422,"author":{"id":"3583781718374593","authorId":"3583781718374593","name":"COGAN","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583781718374593","authorIdStr":"3583781718374593"},"themes":[],"htmlText":"cool","listText":"cool","text":"cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/111099656","repostId":"1132140510","repostType":4,"repost":{"id":"1132140510","pubTimestamp":1622637521,"share":"https://ttm.financial/m/news/1132140510?lang=&edition=fundamental","pubTime":"2021-06-02 20:38","market":"us","language":"en","title":"Singapore Allows Sinovac Vaccine After WHO Emergency Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1132140510","media":"Bloomberg","summary":"Singapore will allow the use of Sinovac Biotech Ltd.’s Covid-19 vaccine, after the World Health Orga","content":"<p>Singapore will allow the use of&nbsp;Sinovac Biotech Ltd.’s Covid-19 vaccine, after the World Health Organization approved the drug as part of its emergency use listing.</p>\n<p>The move means the drug can be administered by private health care providers as part of a program that allows the use of unregistered Covid-19 vaccines, the ministry of health said in a statement Wednesday. The Sinovac vaccine is not part of the national vaccine program.</p>\n<p>The World Health Organization&nbsp;authorized&nbsp;the Sinovac vaccine on June 1, paving the way for a wider rollout in countriesscramblingfor a supply of immunizations. Singapore’s decision comes about three months after the country received its&nbsp;first shipment&nbsp;of&nbsp;200,000 doses&nbsp;of the Sinovac shot on Feb. 23, and amid&nbsp;debate&nbsp;over the efficacy of the vaccine.</p>\n<p>The shot, dubbed CoronaVac, has the lowest efficacy rate reported from clinical trials among the frontrunner wave of vaccines: it was found to be just 50.7% effective in preventing symptomatic Covid in a trial in Brazil, barely crossing the minimum threshold required by drug regulators around the world. But real world evidence is emerging that it’s far more effective on the ground: In a&nbsp;recent study&nbsp;of around 130,000 Indonesia health workers, it protected 94% against symptomatic infection, 96% against hospitalization, and 98% against death.</p>\n<p>Singapore has authorized both the Pfizer Inc.-BioNTech SE and Moderna Inc. vaccines, and has one of the best per-capita vaccination rates in Asia, with&nbsp;about 40%&nbsp;of the population having received their first dose. The Southeast Asian nation is&nbsp;allowing&nbsp;school children to be inoculated from this month, as part of its strategy to reopen the economy.</p>\n<p>The health ministry will release more details in the coming days and is also studying the possibility for private health-care institutions to access the stock of 200,000 doses. It is working out the details on pricing, informed consent process and safety of the patients who prefer this vaccine, it said.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Singapore Allows Sinovac Vaccine After WHO Emergency Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSingapore Allows Sinovac Vaccine After WHO Emergency Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-02 20:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-06-02/singapore-allows-sinovac-vaccine-after-who-emergency-approval?srnd=premium-asia><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Singapore will allow the use of Sinovac Biotech Ltd.’s Covid-19 vaccine, after the World Health Organization approved the drug as part of its emergency use listing.\nThe move means the drug can be ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-06-02/singapore-allows-sinovac-vaccine-after-who-emergency-approval?srnd=premium-asia\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SVA":"科兴生物","STI.SI":"富时新加坡海峡指数"},"source_url":"https://www.bloomberg.com/news/articles/2021-06-02/singapore-allows-sinovac-vaccine-after-who-emergency-approval?srnd=premium-asia","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1132140510","content_text":"Singapore will allow the use of Sinovac Biotech Ltd.’s Covid-19 vaccine, after the World Health Organization approved the drug as part of its emergency use listing.\nThe move means the drug can be administered by private health care providers as part of a program that allows the use of unregistered Covid-19 vaccines, the ministry of health said in a statement Wednesday. The Sinovac vaccine is not part of the national vaccine program.\nThe World Health Organization authorized the Sinovac vaccine on June 1, paving the way for a wider rollout in countriesscramblingfor a supply of immunizations. Singapore’s decision comes about three months after the country received its first shipment of 200,000 doses of the Sinovac shot on Feb. 23, and amid debate over the efficacy of the vaccine.\nThe shot, dubbed CoronaVac, has the lowest efficacy rate reported from clinical trials among the frontrunner wave of vaccines: it was found to be just 50.7% effective in preventing symptomatic Covid in a trial in Brazil, barely crossing the minimum threshold required by drug regulators around the world. But real world evidence is emerging that it’s far more effective on the ground: In a recent study of around 130,000 Indonesia health workers, it protected 94% against symptomatic infection, 96% against hospitalization, and 98% against death.\nSingapore has authorized both the Pfizer Inc.-BioNTech SE and Moderna Inc. vaccines, and has one of the best per-capita vaccination rates in Asia, with about 40% of the population having received their first dose. The Southeast Asian nation is allowing school children to be inoculated from this month, as part of its strategy to reopen the economy.\nThe health ministry will release more details in the coming days and is also studying the possibility for private health-care institutions to access the stock of 200,000 doses. It is working out the details on pricing, informed consent process and safety of the patients who prefer this vaccine, it said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":281,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":true}